Key facts
- Braveheart Bio is targeting a valuation of up to $1.2 billion for its U.S. IPO.
- The company plans to raise $318.8 million by offering 18.8 million shares at $15-$17 each.
- Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy and related cardiovascular diseases.
- Fidelity Management & Research plans to purchase up to $75 million in shares.
- The company intends to list on the Nasdaq under the symbol "BRVE".
Braveheart Bio, a clinical-stage biopharmaceutical company, is aiming for a valuation of up to $1.2 billion in its upcoming U.S. initial public offering. The company plans to raise approximately $318.8 million by offering 18.8 million shares with a price range of $15 to $17 per share.
Based in San Francisco, California, Braveheart Bio focuses on developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its lead product candidate, BHB-1893, is an oral cardiac myosin inhibitor designed to treat obstructive and non-obstructive HCM.
Fidelity Management & Research has indicated interest in purchasing up to $75 million of shares at the IPO price, acting as a cornerstone investor. Since its founding in 2024, Braveheart Bio has secured about $185 million in Series A financing from investors including Andreessen Horowitz, Forbion, and OrbiMed.
The company intends to allocate the IPO proceeds towards advancing the development of BHB-1893, funding research and development activities, and for general corporate purposes. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint bookrunners for the offering. Braveheart Bio plans to list its shares on the Nasdaq Global Market under the ticker symbol "BRVE".